PRN: Endometriosis Drug Forecasts and R&D 2017-2027

16/ago/2017 15:01:37 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Endometriosis Drug Forecasts and R&D 2017-2027


LONDON, August 16, 2017 /PRNewswire/ --

Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets

Endometriosis - our new study reveals trends, R&D progress, and predicted revenues

     (Logo: )

Where is the Endometriosis market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead: 

Our 146-page report provides 108 tables, charts, clearly illustrating the data presented in this research. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted drug sales at overall world market regional level, as well as giving a deep insight into the pipeline for Endometriosis. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Endometriosis market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects 

• In addition to revenue forecasting to 2027, our new study provides you with recent results, R&D overview, growth rates, and market shares.

• You find original analyses, with business outlooks and developments.

• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and following Endometriosis Therapeutics: 

• Lupron

• Eligard

• Zoladex

• Depo-Provera

• Visanne

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 11 leading national markets:

• The US

• Germany

• France

• The UK

• Spain

• Italy

• Japan

• China

• India

• Brazil

• Russia

• RoW

Endometriosis Drug Forecasts and R&D 2017-2027

The report also includes profiles and pipeline analysis for some of the leading companies in the Endometriosis market, with a focus on the Endometriosis segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Germany, France and India in particular, will continue to achieve high revenue growth to 2027.

Leading companies and the potential for market growth 

Overall world revenue for Endometriosis will surpass $3bn in 2027, our work calculates. This will be driven by the development of more effective drugs for the condition as well as raising awareness of Endometriosis over the forecast period

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Endometriosis Market report helps you 

In summary, our 146-page report provides you with the following knowledge:

• Revenue forecasts to 2027 for the Endometriosis market and 5 Leading Therapeutic Drugs for the condition - discover the industry's prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2027 for 11 of the leading national markets - US, Germany, France, UK, Italy, Spain, Russia, Japan, China, India, Brazil

• Discussion of what stimulates and restrains companies and the market

• Prospects for established firms and those seeking to enter the market - including company profiles and R&D overviews for 10 companies involved in developing and manufacturing Endometriosis drugs

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else 

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Endometriosis market and leading companies. You will find data, trends and predictions.

Get our report today Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets. Avoid missing out - get our report now.

To request a report overview of this report please email Sara Peerun at or call Tel: +44-(0)-20-7336-6100

Or click on

Companies Mentioned in This Report: 

Abbott Laboratories


Ablynx NV

AC Immune SA

Active Biotech AB

Addex Therapeutics Ltd.

Advanced Biological Laboratories SA

AEterna Zenaris

Agenus Schweiz AG

Agios Pharmaceuticals, Inc.

Aileron Therapeutics, Inc.

Akari Therapeutics Plc

Allergan Plc

Amanouchi Pharmaceutical Co.

Amgen, Inc.

Anacor Pharmaceuticals, Inc.

AP Avadis Biotechnologies

Apeiron Biologics Ag

Apogenix GmbH

Aquinox Pharmaceuticals, Inc.

ArQule, Inc.

Array BioPharma, Inc.

Astellas Pharma

AstraZeneca Plc

Atrix Laboratories

Bayer HealthCare

BeiGene Ltd.

BioAtla LLC

Biogen, Inc.

BioNTech AG

BioPorto A/S

Bio-Rad Laboratories, Inc.

Celgene Corp.

Celmatix Inc.



Cidara Therapeutics, Inc.

Cogstate Ltd.

Collplant Holdings Ltd.

CRISPR Therapeutics AG

CTI BioPharma Corp.

Cyprotex Plc

CytomX Therapeutics, Inc.

Debiopharm International Sa

DelsiTech Ltd.

Domain Therapeutics SA

Dongkook Pharmaceutical Co.

ElexoPharm GmbH

Eli Lilly

Enanta Pharmaceuticals, Inc.


Epizyme, Inc.

Euroscreen S.A.

Euthymics Bioscience Inc.

Evotec AG

Florida Hospital

Fujisawa Pharmaceutical Co.

Genentech, Inc.

Genzyme Corporation


Halozyme Therapeutics, Inc.

HemoShear Therapeutics LLC

Highland Clinical Research

Hydra Biosciences Inc.

Idera Pharmaceuticals, Inc.

ImmunoGen, Inc.

Immunomedics, Inc.

Inc. Forendo Pharma Oy

Infinity Pharmaceuticals, Inc.

Interleukin Genetics, Inc.

Invivo Therapeutics Holdings Corp.

Isifer AB

Jiangsu Kanion Pharmaceutical Co.

Kissei Pharmaceutical

Lipicard Technologies Limited

Medigene AG

Meditrina Pharmaceuticals

Medivation, Inc.

Mendel Biotechnology Inc.

MorphoSys AG

Mylan NV

Myovant Sciences Ltd.

Neurocrine Biosciences, Inc.

NextCure Inc.


OncoMed Pharmaceuticals, Inc.

OncoTherapy Science, Inc.

OPKO Health, Inc.

Orphagen Pharmaceuticals

Peptidream Inc.



Philogen Spa

Portola Pharmaceuticals, Inc.

PregLem SA

Probiodrug AG

pSivida Corp.

Puma Biotechnology, Inc.

Repros Therapeutics Inc.



Schering AG

SK Chemicals Co.

Takeda Pharmaceutical

Tolmar Therapeutics


To see a report overview please email Sara Peerun on

blog comments powered by Disqus è un servizio offerto da Factotum Srl